A phase 1 study of temsirolimus in combination with gemcitabine in previously untreated metastatic pancreatic cancer.
Phase of Trial: Phase I
Latest Information Update: 14 Oct 2017
At a glance
- Drugs Gemcitabine; Temsirolimus
- Indications Pancreatic cancer
- Focus Adverse reactions
- 01 Dec 2011 Company (Pfizer) added as trial sponsor as reported by ClinicalTrials.gov.
- 01 Dec 2011 Planned number of patients changed from 30 to 5 as reported by ClinicalTrials.gov.
- 01 Dec 2011 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.